Interferons as antiangiogenic agents.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

26 citing papers in PubMed, 75 citations in OpenAlex.

1. Interferon-alpha therapy for refractory kaposiform hemangioendothelioma: a single-center experience.Scientific reports · 2016
   Trial
2. Role of the TLR signaling pathway in the pathogenesis of glioblastoma multiforme with an emphasis on immunotherapy.Biochemistry and biophysics reports · 2025
   Review
3. The Immunotherapeutic Role of Type I and III Interferons in Melanoma and Non-Melanoma Skin Cancers.Life (Basel, Switzerland) · 2023
   Review
4. Injectable biomaterial shuttles for cell therapy in stroke.Brain research bulletin · 2021
   Review
5. Tryptophanyl-tRNA Synthetase as a Potential Therapeutic Target.International journal of molecular sciences · 2021
   Review
6. Up-regulation of indoleamine 2,3-dioxygenase 1 (IDO1) expression and catalytic activity is associated with immunosuppression and poor prognosis in penile squamous cell carcinoma patients.Cancer communications (London, England) · 2020
   Article
7. Production of biologically active feline interferon beta in insect larvae using a recombinant baculovirus.3 Biotech · 2018
   Article
8. Stem Cell-Based Immunomodulation After Stroke: Effects on Brain Repair Processes.Stroke · 2018
   Review
9. Differential growth and responsiveness to cancer therapy of tumor cells in different environments.Clinical & experimental metastasis · 2016
   Article
10. Strategies and developments of immunotherapies in osteosarcoma.Oncology letters · 2016
    Article
11. Pivotal role for decorin in angiogenesis.Matrix biology : journal of the International Society for Matrix Biology · 2015
    Review
12. Treatment of alarming head and neck infantile hemangiomas with interferon-α2a: a clinical study in eleven consecutive patients.Drug design, development and therapy · 2015
    Article
13. Trp-tRNA synthetase bridges DNA-PKcs to PARP-1 to link IFN-γ and p53 signaling.Nature chemical biology · 2012
    Article
14. Endothelial progenitor cells: a new player in lupus?Arthritis research & therapy · 2012
    Review
15. Bioinformatic analysis of patient-derived ASPS gene expressions and ASPL-TFE3 fusion transcript levels identify potential therapeutic targets.PloS one · 2012
    Article
16. Possible angiogenic roles for claudin-4 in ovarian cancer.Cancer biology & therapy · 2009
    Article
17. Phase I analysis of BCNU-impregnated biodegradable polymer wafers followed by systemic interferon alfa-2b in adults with recurrent glioblastoma multiforme.Journal of neuro-oncology · 2008
    Article
18. Regulation of apoptosis by type III interferons.Cell proliferation · 2008
    Article
19. Interferons at age 50: past, current and future impact on biomedicine.Nature reviews. Drug discovery · 2007
    Review
20. STAT1-independent inhibition of cyclooxygenase-2 expression by IFNgamma; a common pathway of IFNgamma-mediated gene repression but not gene activation.Oncogene · 2007
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as